Back to Browse Journals » Vascular Health and Risk Management » Volume 6

Combination therapy of statin and ezetimibe for the treatment of familial hypercholesterolemia

Authors Ian Hamilton-Craig, Karam Kostner, David Colquhoun, et al

Published Date November 2010 Volume 2010:6 Pages 1023—1037

DOI http://dx.doi.org/10.2147/VHRM.S13496

Published 10 November 2010

Ian Hamilton-Craig1, Karam Kostner2, David Colquhoun2, Stan Woodhouse2
1Griffith University School of Medicine, Southport, Queensland, Australia; 2University of Queensland, Brisbane, Queensland, Australia

Abstract: High-dose potent statin therapy in combination with ezetimibe is now standard practice for the treatment of adult patients with heterozygous familial hypercholesterolemia (heFH), as the result of numerous studies in patients with primary hypercholesterolemia or heFH. These studies have shown the combination to be both effective and safe in the short to medium term. Recently, short-term ezetimibe therapy has also been shown to be effective and safe in combination with statin therapy for children and adolescents with heFH. Effective statin–ezetimibe combination therapy is capable of achieving near-normal lipid profiles in heFH patients, with expected improvement in risk for cardiovascular disease (CVD) and improved life expectancy resulting predominantly from reduction in levels of low-density lipoprotein cholesterol. There are few data to support a pleiotropic action of ezetimibe with regard to CVD benefit, unlike therapy with statins. No serious and unexpected clinical adverse effects of combination statin–ezetimibe therapy have emerged till date, although data are limited in children and adolescents, for whom longer-term studies are required. Recent data suggesting possible proatherogenic effects of ezetimibe require confirmation. One large long-term randomized controlled clinical outcomes trial is in progress in non-FH patients to determine the efficacy and safety of ezetimibe therapy; it is unlikely that such a trial will ever be performed in patients with FH.

Keywords: familial hypercholesterolemia, ezetimibe, statin, combination therapy, low-density lipoprotein cholesterol

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other article by this author:

Lipid-modifying therapy in the elderly

Hamilton-Craig I, Colquhoun D, Kostner K, Woodhouse S, d'Emden M

Vascular Health and Risk Management 2015, 11:251-263

Published Date: 14 May 2015

Readers of this article also read:

A cross-sectional study on perception of stigma by Chinese schizophrenia patients [Expression of concern]

Ren ZB, Wang HQ, Feng B, Gu CY, Ma YC, Chen H, Li BL, Liu LY

Neuropsychiatric Disease and Treatment 2014, 10:1333-1334

Published Date: 18 July 2014

Causal diagrams and the logic of matched case-control studies [Corrigendum]

Shahar E, Shahar DJ

Clinical Epidemiology 2014, 6:59-60

Published Date: 22 January 2014

Prescribing tests must have curriculum support

Lemon TI, Shah RD

Advances in Medical Education and Practice 2013, 4:91-93

Published Date: 7 May 2013

Preparation, characterization, and in vitro and in vivo investigation of chitosan-coated poly (d,l-lactide-co-glycolide) nanoparticles for intestinal delivery of exendin-4

Wang M, Zhang Y, Feng J, Gu T, Dong Q, Yang X, Sun Y, Wu Y, Chen Y, Kong W

International Journal of Nanomedicine 2013, 8:1141-1154

Published Date: 15 March 2013

Erratum

Marusza W, Mlynarczyk G, Olszanski R, Netsvyetayeva I, Obrowski M, Iannitti T, Palmieri B

International Journal of Nanomedicine 2012, 7:4119-4120

Published Date: 27 July 2012

Enhancing cellular uptake of activable cell-penetrating peptide–doxorubicin conjugate by enzymatic cleavage

Shi NQ, Gao W, Xiang B, Qi XR

International Journal of Nanomedicine 2012, 7:1613-1621

Published Date: 26 March 2012

Bactericidal effect of iron oxide nanoparticles on Staphylococcus aureus

Nhiem Tran, Aparna Mir, Dhriti Mallik, et al

International Journal of Nanomedicine 2010, 5:277-283

Published Date: 14 April 2010

Prevalence of risk factors, coronary and systemic atherosclerosis in abdominal aortic aneurysm: Comparison with high cardiovascular risk population

Alberto Palazzuoli, Maddalena Gallotta, Giuseppe Guerrieri, Ilaria Quatrini, Beatrice Franci, et al

Vascular Health and Risk Management 2008, 4:877-883

Published Date: 7 September 2008